Chondroitin sulfate proteoglycan 4 (CSPG4), formerly called melanoma-associated chondroitin sulfate proteoglycan (MCSP) or high-molecular-weight melanoma-associated antigen (HMW-MAA), has attracted attention as a target structure for CAR-T-cell therapy in recent years due to a number of reasons [7], including the expression on a broad variety of malignancies, such as melanoma, glioblastoma, leukemia, and breast cancer [7]. This evidence concerns the gene CSPG4 and glioblastoma.